Page 1608 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 87 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma 1431.e3

97. Isaac J, Herrera GA: Cast nephropathy in a case of Waldenström’s 121. Feiner HD, Rizk CC, Finfer MD, et al: IgM monoclonal gammopathy/
macroglobulinemia. Nephron 91:512, 2002. Waldenström’s macroglobulinemia: a morphological and immunophe-
98. Morel-Maroger L, Basch A, Danon F, et al: Pathology of the kidney in notypic study of the bone marrow. Mod Pathol 3:348, 1990.
Waldenström’s macroglobulinemia: study of sixteen cases. N Engl J Med 122. Dutcher TF, Fahey JL: The histopathology of macroglobulinemia of
283:123, 1970. Waldenström. J Natl Cancer Inst 22:887, 1959.
99. Gertz MA, Kyle RA, Noel P: Primary systemic amyloidosis: a rare 123. Hunter ZR, Manning RJ, Hanzis C, et al: IgA and IgG hypogam-
complication of immunoglobulin M monoclonal gammopathies and maglobulinemia in Waldenström’s macroglobulinemia. Haematologica
Waldenström’s macroglobulinemia. J Clin Oncol 11:914, 1993. 95:470, 2010.
100. Moyner K, Sletten K, Husby G, et al: An unusually large (83 amino acid 124. Stone MJ, Bogen SA: Evidence-based focused review of management
residues) amyloid fibril protein AA from a patient with Waldenström’s of hyperviscosity syndrome. Blood 119:2205, 2012.
macroglobulinaemia and amyloidosis. Scand J Immunol 11:549, 1980. 125. Menke MN, Treon SP: Hyperviscosity syndrome. In Sekeres MA,
101. Gardyn J, Schwartz A, Gal R, et al: Waldenström’s macroglobulinemia Kalaycio M, Bolwell BJ, editors: Clinical malignant hematology, New
associated with AA amyloidosis. Int J Hematol 74:76, 2001. York, 2007, McGraw-Hill, p 937.
102. Dussol B, Kaplanski G, Daniel L, et al: Simultaneous occurrence of 126. Moulopoulos LA, Dimopoulos MA, Varma DG, et al: Waldenström
fibrillary glomerulopathy and AL amyloid. Nephrol Dial Transplant macroglobulinemia: MR imaging of the spine and CT of the abdomen
13:2630, 1998. and pelvis. Radiology 188:669, 1993.
103. Rausch PG, Herion JC: Pulmonary manifestations of Waldenström 127. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria
macroglobulinemia. Am J Hematol 9:201, 1980. to initiate therapy in Waldenström’s macroglobulinemia: consensus
104. Fadil A, Taylor DE: The lung and Waldenström’s macroglobulinemia. panel recommendations from the Second International Workshop on
South Med J 91:681, 1998. Waldenström’s Macroglobulinemia. Semin Oncol 30:116, 2003.
105. Kyrtsonis MC, Angelopoulou MK, Kontopidou FN, et al: Primary 128. Dimopoulos MA, Kastritis E, Owen RG, et al: Treatment recommen-
lung involvement in Waldenström’s macroglobulinaemia: report of two dations for patients with Waldenström macroglobulinemia (WM) and
cases and review of the literature. Acta Haematol 105:92, 2001. related disorders: IWWM-7 consensus. Blood 124:1404, 2014.
106. Kaila VL, el Newihi HM, Dreiling BJ, et al: Waldenström’s macro- 129. Kyle RA, Greipp PR, Gertz MA, et al: Waldenström’s macroglobu-
globulinemia of the stomach presenting with upper gastrointestinal linaemia: a prospective study comparing daily with intermittent oral
hemorrhage. Gastrointest Endosc 44:73, 1996. chlorambucil. Br J Haematol 108:737, 2000.
107. Yasui O, Tukamoto F, Sasaki N, et al: Malignant lymphoma of the 130. Dimopoulos MA, Alexanian R: Waldenström’s macroglobulinemia.
transverse colon associated with macroglobulinemia. Am J Gastroenterol Blood 83:1452, 1994.
92:2299, 1997. 131. Petrucci MT, Avvisati G, Tribalto M, et al: Waldenström’s macroglobu-
108. Rosenthal JA, Curran WJ, Jr, Schuster SJ: Waldenström’s macroglobu- linaemia: results of a combined oral treatment in 34 newly diagnosed
linemia resulting from localized gastric lymphoplasmacytoid lymphoma. patients. J Intern Med 226:443, 1989.
Am J Hematol 58:244, 1998. 132. Case DC, Jr, Ervin TJ, Boyd MA, et al: Waldenström’s macroglobu-
109. Recine MA, Perez MT, Cabello-Inchausti B, et al: Extranodal lym- linemia: long-term results with the M-2 protocol. Cancer Invest 9:1,
phoplasmacytoid lymphoma (immunocytoma) presenting as small 1991.
intestinal obstruction. Arch Pathol Lab Med 125:677, 2001. 133. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Walden-
110. Veltman GA, van Veen S, Kluin-Nelemans JC, et al: Renal disease in ström’s macroglobulinemia: a report of 167 cases. J Clin Oncol 11:1553,
Waldenström’s macroglobulinaemia. Nephrol Dial Transplant 12:1256, 1993.
1997. 134. Leblond V, Johnson S, Chevret S, et al: Results of a randomized trial
111. Moore DF, Jr, Moulopoulos LA, Dimopoulos MA: Waldenström of chlorambucil versus fludarabine for patients with Waldenström
macroglobulinemia presenting as a renal or perirenal mass: clinical and macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic
radiographic features. Leuk Lymphoma 17:331, 1995. lymphoma. J Clin Oncol 31:301, 2013.
112. Mascaro JM, Montserrat E, Estrach T, et al: Specific cutaneous mani- 135. Dimopoulos MA, Kantarjian H, Weber D, et al: Primary therapy of
festations of Waldenström’s macroglobulinaemia: a report of two cases. Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J
Br J Dermatol 106:17, 1982. Clin Oncol 12:2694, 1994.
113. Schnitzler L, Schubert B, Boasson M, et al: Urticaire chronique, lésions 136. Delannoy A, Ferrant A, Martiat P, et al: 2-Chlorodeoxyadenosine
osseuses, macroglobulinémie IgM: maladie de Waldenström? Bull Soc therapy in Waldenström’s macroglobulinaemia. Nouv Rev Fr Hematol
Fr Dermatol Syphiligr 81:363, 1974. 36:317, 1994.
114. Roux S, Fermand JP, Brechignac S, et al: Tumoral joint involvement in 137. Fridrik MA, Jäger G, Baldinger C, et al: First-line treatment of Walden-
multiple myeloma and Waldenström’s macroglobulinemia—report of 4 ström’s disease with cladribine. Ann Hematol 74:7, 1997.
cases. J Rheumatol 23:2175, 1996. 138. Liu ES, Burian C, Miller WE, et al: Bolus administration of cladribine
115. Orellana J, Friedman AH: Ocular manifestations of multiple myeloma, in the treatment of Waldenström macroglobulinaemia. Br J Haematol
Waldenström’s macroglobulinemia and benign monoclonal gammopa- 103:690, 1998.
thy. Surv Ophthalmol 26:157, 1981. 139. Hellmann A, Lewandowski K, Zaucha JM, et al: Effect of a 2-hour
116. Ettl AR, Birbamer GG, Philipp W: Orbital involvement in Walden- infusion of 2-chlorodeoxyadenosine in the treatment of refractory or
ström’s macroglobulinemia: ultrasound, computed tomography and previously untreated Waldenström’s macroglobulinemia. Eur J Haema-
magnetic resonance findings. Ophthalmologica 205:40, 1992. tol 63:35, 1999.
117. Civit T, Coulbois S, Baylac F, et al: Waldenström’s macroglobulinemia 140. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al: Cladribine
and cerebral lymphoplasmacytic proliferation: Bing and Neel syndrome. (2-CDA) given as subcutaneous bolus injections is active in pretreated
Report of a new case [in French]. Neurochirurgie 43:245, 1997. Waldenström’s macroglobulinaemia. Swiss Group for Clinical Cancer
118. Ciccarelli BT, Patterson CJ, Hunter ZR, et al: Hepcidin is produced by Research (SAKK). Br J Haematol 99:358, 1997.
lymphoplasmacytic cells and is associated with anemia in Waldenström’s 141. Dimopoulos MA, Weber D, Delasalle KB, et al: Treatment of
macroglobulinemia. Clin Lymphoma Myeloma Leuk 11:160, 2011. Waldenström’s macroglobulinemia resistant to standard therapy with
119. Treon SP, Tripsas C, Ciccarelli BT, et al: Patients with Waldenström 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol
macroglobulinemia commonly present with iron deficiency and those 6:49, 1995.
with severely depressed transferrin saturation levels show response to 142. Dimopoulos MA, O’Brien S, Kantarjian H, et al: Fludarabine therapy
parenteral iron administration. Clin Lymphoma Myeloma Leuk 13:241, in Waldenström’s macroglobulinemia. Am J Med 95:49, 1993.
2013. 143. Foran JM, Rohatiner AZ, Coiffier B, et al: Multicenter phase II
120. Owen RG, Barrans SL, Richards SJ, et al: Waldenström macroglobulin- study of fludarabine phosphate for patients with newly diagnosed
emia: development of diagnostic criteria and identification of prognostic lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia,
factors. Am J Clin Pathol 116:420, 2001. and mantle-cell lymphoma. J Clin Oncol 17:546, 1999.